| 罗格列酮对2型糖尿病冠脉介入术后再狭窄的预防作用 |
| |
| 引用本文： | 余英,江洪.罗格列酮对2型糖尿病冠脉介入术后再狭窄的预防作用[J].心血管病学进展,2006,27(1):82-85. |
| |
| 作者姓名： | 余英 江洪 |
| |
| 作者单位： | 武汉大学人民医院心血管内科,湖北,武汉,430060 |
| |
| 摘 要： | 冠状动脉介入治疗术在临床上已经得到了广泛应用,但冠状动脉介入治疗术后再狭窄的发生率依然较高,合并有2型糖尿病的患者尤甚,再狭窄严重阻碍了冠状动脉介入治疗的临床运用,罗格列酮对预防2型糖尿病患者冠状动脉介入治疗术后再狭窄的发生有较好的疗效,其具体作用机制有:减轻炎症反应、抑制血管平滑肌细胞增殖和迁移、保护血管内皮细胞、减轻胰岛素抵抗、改善高凝状态、增强脂联素的作用等。
|
| 关 键 词： | 罗格列酮 再狭窄 2型糖尿病 |
| 文章编号： | 1004-3934(2006)01-0082-04 |
| 收稿时间： | 2005-06-29 |
| 修稿时间： | 2005-09-14 |
Rosiglitazone in Prevention of Restenosis After Percutaneous Coronary Intervention in Type 2 Diabetes Mellitus |
| |
| YU Ying,JIANG Hong.Rosiglitazone in Prevention of Restenosis After Percutaneous Coronary Intervention in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2006,27(1):82-85. |
| |
| Authors: | YU Ying JIANG Hong |
| |
| Abstract: | Despite the popularity of percutaneous coronary intervention(PCI)in coronary artery disease,restenosis remains a challenging clinical problem,and patients accompanied by type 2 diabetes mellitus have higher rate of restenosis which do harm to long-term effect.The prospect of rosiglitazone in prevention of restenosis after PCI in type 2 diabetes mellitus has been displayed.Rosiglitazone can reduce inflammatory responses,inhibit the growth factorinduced proliferation and migration of vascular smooth muscle cell,strengthen the effect of adiponectin,reduce the cardiovascular risks on the aspects related to insulin resistance,including lipid metabolism,vascular reactivity,endothelial function,coagulation,vessel wall,body fat distribution and ameliorating atherosclerosis and prevent coronary artery restenosis. |
| |
| Keywords: | rosiglitazone restenosis type 2 diabetes mellitus |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
